How Infections Cause One in Eight Cancers

Here is a detailed Episode Description for your Audio Overview, fully grounded in the landmark study published in The Lancet Oncology and structured to fit under 10,000 characters.

Podcast Episode Description: How Infections Cause One in Eight Cancers

Episode Title: How Infections Cause One in Eight Cancers: Global Burden, Key Pathogens, and Prevention
Series: Gemini Notebook Audio Overview
Source Attribution: Based on research by Rumgay et al. published in The Lancet Oncology (Read Full Article on The Lancet).

Episode Summary

Did you know that nearly one in eight new cancer cases worldwide (12%) is caused by a preventable or treatable infection?

In this episode, we explore an updated worldwide incidence study published in The Lancet Oncology by researchers at the International Agency for Research on Cancer (IARC/WHO). Drawing on 2024 global cancer data across 186 countries, the episode breaks down how 12 Group 1 carcinogenic infectious agents—including bacteria, viruses, and parasites—drive 2.3 million new cancer diagnoses each year.

We examine the primary infectious drivers of cancer, highlight stark global inequities where low- and middle-income countries bear three-quarters of the global burden, and discuss actionable public health strategies—from vaccines to screen-and-treat programs—that could dramatically reduce global cancer incidence.

Key Topics & Discussion Points

• The Global Scale of Infection-Driven Cancers:
  • The 12% Fraction: Out of 20 million new cancer cases in 2024, an estimated 2.3 million were attributable to infectious agents classified as Group 1 carcinogens by the IARC Monographs Programme.
  • The Top 5 Infectious Culprits:
    1. Helicobacter pylori (760,000 cases / 4% of all cancers): The single largest infectious cause of cancer globally, responsible for 85% of non-cardia gastric cancers and 74% of gastric MALT lymphomas.
    2. Human Papillomavirus (HPV) (750,000 cases / 4% of all cancers): Drives 100% of cervical cancers (with high-risk genotypes HPV16 and HPV18 alone causing nearly 75%), as well as significant proportions of oropharyngeal, anal, penile, vaginal, and vulvar cancers.
    3. Hepatitis B Virus (HBV) (360,000 cases) & Hepatitis C Virus (HCV) (160,000 cases): Major drivers of liver cancer (hepatocellular carcinoma) and bile duct cancer (intrahepatic cholangiocarcinoma).
    4. Epstein–Barr Virus (EBV) (260,000 cases): Now recognized as the fourth leading infectious cause of cancer globally due to expanded evidence linking EBV to gastric cancers and multiple lymphoma types (nasopharyngeal cancer, Burkitt lymphoma, Hodgkin lymphoma, and DLBCL).
    5. Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) (35,000 cases): Responsible for 100% of Kaposi's sarcoma cases and primary effusion lymphoma.
  • Other Carcinogenic Pathogens: Including HIV (driving cancers through immunosuppression), HTLV-1 (adult T-cell leukemia/lymphoma), Merkel cell polyomavirus (MCV), and parasitic infections such as Schistosoma haematobium (bladder cancer) and liver flukes (Opisthorchis viverrini / Clonorchis sinensis).
• Geographical Disparities & Regional Hotspots:
  • Low- and Middle-Income Countries: Bear 77% of all infection-attributable cancer cases worldwide.
  • Eastern Asia (990,000 cases / 42% of global total): Holds the highest regional burden globally, heavily driven by H. pylori (410,000 cases) and HBV (260,000 cases).
  • Sub-Saharan Africa: Has the highest proportional burden of HPV-attributable cancer (PAF 14%, ASIR 16.6 per 100,000 person-years), alongside significant burdens of KSHV and HIV-associated malignancies.
  • Specific Regional Drivers: High HCV-related liver cancer burden in Northern Africa (notably Egypt), high H. pylori rates in Central/Eastern Europe, and elevated EBV-attributable nasopharyngeal cancer in Southeastern Asia.
• Public Health Prevention Roadmap:
  • Primary Prevention: Scaling up single-dose and gender-neutral HPV vaccination, neonatal HBV immunization, safe injection practices, condom distribution, and long-acting HIV Pre-Exposure Prophylaxis (PrEP).
  • Secondary Prevention: Expanding H. pylori screen-and-treat interventions, endoscopic screening in high-risk zones, cervical/anal precancerous lesion screening, and access to direct-acting antivirals for HBV/HCV.
  • R&D Priorities: Accelerating investment in new preventive vaccines targeting EBV and KSHV, as well as blood-based biomarkers for early cancer detection.

Official Citation & Source Article

• Article Title: Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis
• Authors: Harriet Rumgay, Damien Georges, Yue Huang, Mayo Hirabayashi, Richa Shah, Catherine de Martel, Jin Young Park, Isabelle Soerjomataram, Gary M Clifford
• Journal: The Lancet Oncology, Vol. 27, Pages 1237–1248 (2026)
• Full Article URL: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00307-4/fulltext

💡 Would you like me to create additional episode materials—such as timestamped chapter markers, key discussion questions, or a summary social media post?